Form 4: Soleno Therapeutics CFO James Mackaness Reports Acquisition of Shares and Stock Options

James Mackaness, CFO of Soleno Therapeutics, reports the acquisition of common stock and stock options.

Summary

• James Mackaness, the Chief Financial Officer of Soleno Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of 14,500 shares of common stock and 31,000 employee stock options on January 21, 2025.
• The common stock was acquired at a price of $0.
• Following the reported transactions, Mackaness beneficially owns 125,798 shares of common stock and 31,000 derivative securities.
• The stock options have an exercise price of $49.17 and expire on January 21, 2035, with vesting occurring monthly starting February 1, 2025.
• The filing was signed on January 23, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock transactions. The acquisition of shares and options by the CFO could be interpreted as a positive signal, but it's a routine occurrence.

Positives

• The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Soleno Therapeutics.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, common stock, Soleno Therapeutics, Mackaness, CFO